(1.20%) 5 070.55 points
(0.69%) 38 504 points
(1.59%) 15 697 points
(0.12%) $83.46
(1.32%) $1.836
(-0.28%) $2 335.60
(-0.26%) $27.29
(-0.08%) $922.10
(-0.05%) $0.934
(-0.09%) $10.89
(-0.05%) $0.803
(0.01%) $93.20
@ $403.95
Issued: 22 Apr 2024 @ 15:04
Return: 0.24%
Previous signal: Apr 19 - 15:18
Previous signal:
Return: 2.74 %
Live Chart Being Loaded With Signals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...
Stats | |
---|---|
Today's Volume | 1.07M |
Average Volume | 1.22M |
Market Cap | 104.59B |
EPS | $0 ( 2024-02-05 ) |
Next earnings date | ( $4.10 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 29.17 |
ATR14 | $3.27 (0.81%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Sachs Bruce I | Buy | 109 | Deferred Stock Units |
2024-04-01 | Ambrose Kristen | Sell | 225 | Common Stock |
2024-04-02 | Ambrose Kristen | Sell | 240 | Common Stock |
2024-02-23 | Wagner Charles F Jr | Sell | 3 309 | Common Stock |
2024-02-23 | Tatsis Ourania | Sell | 3 309 | Common Stock |
INSIDER POWER |
---|
11.73 |
Last 100 transactions |
Buy: 259 544 | Sell: 201 703 |
Volume Correlation
Vertex Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vertex Pharmaceuticals Correlation - Currency/Commodity
Vertex Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $9.84B |
Gross Profit: | $8.58B (87.17 %) |
EPS: | $14.05 |
Q4 | 2023 |
Revenue: | $2.52B |
Gross Profit: | $2.15B (85.38 %) |
EPS: | $3.76 |
Q3 | 2023 |
Revenue: | $2.48B |
Gross Profit: | $2.16B (87.17 %) |
EPS: | $4.01 |
Q2 | 2023 |
Revenue: | $2.49B |
Gross Profit: | $2.18B (87.62 %) |
EPS: | $3.55 |
Financial Reports:
No articles found.
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators